The health authorities warned that taking JAK inhibitors, which are used as a treatment for rheumatoid arthritis, could cause serious heart problems such as heart attacks. The target items are Tofacitinib, Baricitinib, and Upadacitinib, which have been actively used in the market recently, so medical professionals will need to examine them more closely. Sales in related markets are expected to be rapidly reduced as the FDA will restrict the drug to certain patients who do not respond to TNF inhibitors or are not drug resistant.

The MFDS includes Tofacitinib, Baricitinib, and Upadacitinib, which are used in the treatment of rheumatoid arthritis. The company announced that it has distributed the Dear Heal